Home / Clients / Case Studies
Case Studies
  •   Advisory & Commercial Support  

    • Exalenz Case - Advisory & Commercial Support


      Situation:

      Exalenz Biosciences is a company that develops and commercializes breakthrough breath-based diagnostics for gastric and liver diseases, sought to generate revenue for their product, H. pylori diagnostic kit, while working on longer-term products.


      Approach:

      Exalenz engaged Extera as its US commercialization arm. Extera functioned as an integral part of the management team, leading pre-launch planning, supporting ongoing operations and expanding commercial infrastructure.


      Results:

      • Established critical agreements with operational partners
      • Formed partnerships with national distributors and created indirect sales channels
      • Successful US product launch in 2010
      • Supported executive team recruitment in the US for on-going management and expansion of commercialization

      Link to Article
  •   BioAssets Development Corp & Cephalon  

    • BDC & Cephalon Deal

      Situation:

      • Novel use IP for anti-TNF in spine disorders / pain
      • Sought funding / future exist

      Approach:
      • Fundraising focused on angels
      • In-licensing biosimilar for trial
      • Exploratory partnering efforts


      Results:

      • 2 Angel financing rounds
      • $30M Cephalon option to acquire + $100M in MS; exercised early



  •   Coley Pharmaceutical Group & Pfizer  

    • Coley & Pfizer Deal

       

      Situation:

      • Multiple immunotherapy assets
      • Sought partner for novel Phase 2 oncology program

       

      Approach:

      • Suspended outreach
      • Re-launched at ASCO targeting emerging oncology companies


      Results:

      • $600M ($50M upfront) Pfizer deal
      • Commitment to Phase 3 trials
      • $110M IPO with $10M from Pfizer


      Link to Article

       

      Note: Deal was led by S. Bernitz prior to joining Extera Partners, as CBO at Coley


  •   Concert Pharmaceuticals & GlaxoSmithKline  

    • Concert & GSK Alliance

      Situation:

      • Numerous early stage assets
      • Sought partner to advance programs / validate technology


      Approach:

      • Focused on HIV program with strongest preclinical PoC
      • Targeted non-conflicted HIV companies

       

      Results:

      • $1B GSK alliance for preclinical programs with $353M upfront + $12M near-term MS

       

      Link to Article


      Note: Deal was led by S. Bernitz prior to joining Extera Partners, as CBO at Concert Pharmaceuticals, Inc

       

  •   German Market Entry  

    • Paieon Case - German Market Entry

      Situation:

      Paieon is a pioneer in the field of real-time imaging for cardiac navigation. The company offers two innovative imaging workstations for Percutaneous Coronary Intervention and Transcatheter Aortic Valve replacement.


      Approach:
      Extera managed the company's pre-commercial and initial commercial activities in Europe with focus on German speaking countries. This included planning, building KOL support, strategic sales and installations in key medical centers and contracting and management of distribution channels.

       

      Results:

      • Network of Key Opinion Leaders in Europe
      • Critical installations in German strategic medical centers
      • Distribution agreements in place in key German speaking markets
      • Training support for, and education of, distributors